Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 14/20 | 0.77 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719178 | 0.91 | KCNK3 (0.84) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17719024 | 0.91 | KCNK3 (0.82) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17719158 | 0.89 | KCNK3 (0.80) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17719026 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17718956 | 0.87 | SLC2A1 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17718941 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17719027 | 0.86 | KCNK3 (0.75) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17718955 | 0.85 | SLC2A1 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17709590 | 0.85 | SLC2A1 (0.80) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL17719179 | 0.85 | SLC2A2 (0.85) | KCNK3KCNK9SLC2A1SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-01 | — | — | US | disclosed |
| EP-3386979-B1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF THE TASK-1 AND TASK-2 CHANNELS FOR TREATING SLEEP-RELATED BREATHING DISORDERS | Bayer Pharma AG (DE) | 2020-07-29 | — | — | EP | disclosed |
| WO-2017097792-A1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-15 | — | — | WO | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | KCNK3 2898/4885KCNK9 2405/4885SLC2A1 6/4885 |
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | TRPV2, CACNA1G, KCNJ2 | KCNK3 85/4885KCNK9 204/4885SLC2A1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.